Takeda Discontinues TAK-128 Clinical Program For Peripheral Diabetic Neuropathy
This article was originally published in PharmAsia News
Executive Summary
Takeda is discontinuing development of a Phase II compound, TAK-128, for the treatment of peripheral diabetic neuropathy after the candidate failed to show sufficient efficacy to support its continued development, the company reported